Author

S. G. Michael

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Biochemistry· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 4 Assay:proteomics· 1 Organism:virus· 1

Frequent Co-Authors

C. Klumpp-Thomas· 4 shared C. Z. Chen· 4 shared H. Guo· 4 shared M. Shen· 4 shared P. Shinn· 4 shared W. Zheng· 4 shared M. Xu· 3 shared A. Simeonov· 2 shared

Activity by Year

2020-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersPharmacology & Toxicology

C. Klumpp-Thomas

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

A Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19

J. H. Shrimp, J. Janiszewski, C. Z. Chen, M. Xu, K. M. Wilson, S. C. Kales, P. E. Sanderson, P. Shinn, Z. Itkin, H. Guo, M. Shen, C. Klumpp-Thomas, S. G. Michael, W. Zheng, A. Simeonov, M. D. Hall

The paper develops and validates a series of assays to identify TMPRSS2 inhibitors as potential COVID-19 treatments, identifying six compounds with varying clinical statuses.

bioRxiv · Feb 4, 2022Biochemistry

Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2

C. Z. Chen, P. Shinn, Z. Itkin, R. Eastman, R. Bostwick, L. Rasmussen, R. Huang, M. Shen, X. Hu, K. M. Wilson, B. Brooks, H. Guo, T. Zhao, C. Klumpp-Thomas, A. Simeonov, , W. Zheng

The paper identifies 319 compounds with anti-SARS-CoV-2 activities through a high-throughput screen, including 91 approved drugs and 49 investigational drugs, with 230 compounds previously unreported.

bioRxiv · Aug 18, 2020Microbiology

Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening

W. Zhu, M. Xu, C. Z. Chen, H. Guo, M. Shen, X. Hu, P. Shinn, C. Klumpp-Thomas, S. G. Michael, W. Zheng

This study identifies 23 SARS-CoV-2 3CLpro inhibitors through high-throughput screening, with several showing potent activity against viral infection.

bioRxiv · Jul 17, 2020Pharmacology & Toxicology

Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS- S and MERS-S pseudotyped particles

C. Z. Chen, M. Xu, M. Pradhan, K. Gorshkov, J. Petersen, M. R. Straus, W. Zhu, P. Shinn, H. Guo, M. Shen, C. Klumpp-Thomas, S. G. Michael, J. Zimmerberg, W. Zheng, G. R. Whittaker

This paper identifies six broad-spectrum inhibitors of SARS-CoV-2 and MERS-CoV spike-mediated cell entry through drug repurposing screens using pseudotyped particles.

bioRxiv · Jul 10, 2020Pharmacology & Toxicology